Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:43:17.945Z.
Calculation as of: 2026-10-06T19:43:17.945Z.
Quote observation: 2026-10-06T19:40:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69957a8c264286ff6eaa706b48c8270e863bf40c8b9bfd4321b5f2d082882a11
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Sionna Therapeutics, Inc.
Market Cap
$210.85M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$210.90M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$210.80M
Price/FCF Ratio
N/A
TTM Avg
4.17
3Y Avg
4.17
5Y Avg
4.17
Market Cap
$212.25M
Price/FCF Ratio
37.41
TTM Avg
48.24
3Y Avg
64.03
5Y Avg
64.30
Market Cap
$214.35M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$205.80M
Price/FCF Ratio
N/A
TTM Avg
400.72
3Y Avg
400.72
5Y Avg
400.72
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | $210.85M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $210.85M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $210.90M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.80M | N/A | 4.17 | 4.17 | 4.17 |
| Niagen Bioscience Inc (NAGE)vs › | $212.25M | 37.41 | 48.24 | 64.03 | 64.30 |
| Pro-Dex, Inc. (PDEX)vs › | $209.25M | 30.36 | 28.19 | 28.69 | 27.64 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.74M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.35M | N/A | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | N/A | 400.72 | 400.72 | 400.72 |
| Electra Therapeutics Inc. (ETRA)vs › | $205.44M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
